Iovance Biotherapeutics, Inc.
NASDAQ:IOVABiotechnology
Healthcare
$7.48 -0.89%
-$0.04 today
- Market cap
- $3.46B
- Beta
- 0.70
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.85
52W Low $1.66High $5.63
Volume 6.99M
Average 14.09M
Income Statement
Follow revenue through to earnings.
Revenue
$263.50M
FY 2025 · Annual
+60.6% YoYOperating Income
-$398.21M
FY 2025 · Annual
Net Income
-$390.98M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.19M | 164.07M | 263.5M |
| Cost of Revenue | 0 | 0 | 10.76M | 124M | 173.18M |
| Gross Profit | 0 | 0 | (9.57M) | 40.08M | 90.32M |
| Gross Margin | — | — | -804.5% | 24.4% | 34.3% |
| Research & Development | 259.04M | 294.78M | 344.08M | 282.34M | 300.27M |
| Selling, General & Admin | 83.66M | 104.1M | 106.92M | 153.02M | 152.32M |
| Operating Expenses | 342.7M | 398.88M | 450.99M | 435.35M | 488.53M |
| Depreciation & Amortization | 13.98M | 21.14M | 33.13M | 43.61M | 47.32M |
| EBITDA | (328.27M) | (371.77M) | (414.39M) | (331.4M) | (350.89M) |
| EBITDA Margin | — | — | -34851.9% | -202.0% | -133.2% |
| Operating Income | (342.7M) | (398.88M) | (460.56M) | (395.28M) | (398.21M) |
| Operating Margin | — | — | -38735.0% | -240.9% | -151.1% |
| Interest Income | 451K | 2.99M | 13.04M | 20.27M | 10.31M |
| Interest Expense | 0 | 2.99M | 0 | 0 | 0 |
| Other Income / Expenses | 451K | 2.99M | 13.04M | 20.27M | 5.16M |
| Income Before Tax | (342.25M) | (395.89M) | (447.52M) | (375.01M) | (393.05M) |
| Pre-Tax Margin | — | — | -37638.0% | -228.6% | -149.2% |
| Income Tax Expense | 0 | 0 | (3.48M) | (2.83M) | (2.07M) |
| Net Income | (342.25M) | (395.89M) | (444.04M) | (372.18M) | (390.98M) |
| Net Margin | — | — | -37345.4% | -226.8% | -148.4% |
| EPS (Basic) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| EPS (Diluted) | (2.23) | (2.49) | (1.89) | (1.28) | (1.09) |
| 153.41M | 159.26M | 235.13M | 289.88M | 357.35M | |
| 153.41M | 159.26M | 235.13M | 289.88M | 357.35M |
IOVA Earnings Waterfall · TTM
NASDAQ:IOVA · Revenue to Net Income
Key Ratios
EPS$-0.53
Gross Margin51.8%
Net Margin-64.9%
P/E Ratio-23.0
P/S Ratio27.0
Analysis
$379.0M of revenue converted into -$220.5M of net income for the selected period. Gross margin is 51.8% and net margin is -64.9%, showing how much revenue survives after costs and taxes. EPS is $-0.53, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 13, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 |
How much revenue does IOVA generate?
Iovance Biotherapeutics, Inc. (IOVA) reported $263.50M of revenue in fiscal 2025.
Is IOVA profitable?
Iovance Biotherapeutics, Inc. (IOVA) reported -$390.98M of net income, with a net margin of -148.4%.
Continue the stock analysis
Jump to another research area for this company.